Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Boehringer Ingelheim
Mallinckrodt
McKinsey
Medtronic

Last Updated: January 29, 2022

DrugPatentWatch Database Preview

Claims for Patent: 10,166,181


Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,166,181
Title:Slow release pharmaceutical composition made of microgranules
Abstract: Pharmaceutical composition made of microparticles for the slow release of an active substance at least during a period covering the 6th month after injection of said composition, said composition comprising a group of microparticles made of a copolymer of the PLGA type which incorporate an active substance in the form of a water insoluble peptide salt; said copolymer furthermore comprising at least 75% of lactic acid and an inherent viscosity between 0.1 and 0.9 dl/g, as measured in chloroform at 25.degree. C. and at a polymer concentration of 0.5 g/dL; said microparticles furthermore having a size distribution defined as follows: --D (v,0.1) is between 10 and 30 micrometers, --D (v,0.5) is between 30 and 70 micrometers, --D (v,0.9) is between 50 and 1 10 micrometers.
Inventor(s): Ducrey; Bertrand (Martigny, CH), Garrouste; Patrick (Saxon, CH), Curdy; Catherine (Riehen, CH), Bardet; Marie-Anne (Maracon, CH), Porchet; Herve (Cugy, CH), Lundstrom; Eija (Lutry, CH), Heimgartner; Frederic (Marin-Epagnier, CH)
Assignee: Debiopharm Research & Manufacturing SA (CH)
Application Number:12/601,649
Patent Claims: 1. A pharmaceutical composition of microgranules comprising 22.5 mg triptorelin in the form of triptorelin pamoate, wherein the pharmaceutical composition comprises: a) a first formulation of microgranules comprising approximately 20% (w/w) of triptorelin pamoate mixed with approximately 80% (w/w) PLGA, wherein the PLGA in the first formulation contains approximately 85% lactide and 15% glycolide; and b) a second formulation of microgranules comprising approximately 12% (w/w) triptorelin pamoate mixed with approximately 88% (w/w) poly(D,L lactide-co-glycolide) (PLGA), wherein the PLGA in the second formulation contains approximately 75% lactide and 25% glycolide, wherein the triptorelin is released from the pharmaceutical composition in an immediate amount within hours following injection and then constantly released over a period of at least 168 days.

2. The pharmaceutical composition of claim 1, wherein the first formulation of microgranules and the second formulation of microgranules are mixed to have a 50:50 dose ratio of triptorelin.

3. The pharmaceutical composition of claim 2, wherein the pharmaceutical composition induces chemical castration in patients over a six-month period of time.

4. The pharmaceutical composition of claim 2, wherein the pharmaceutical composition induces chemical castration in patients with advanced prostate cancer.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Colorcon
Merck
Moodys
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.